44 stories
BPC-157 is a synthetic 15-amino-acid fragment derived from a gastric protein. It became one of the most-requested research peptides in the wellness and longevity market on the strength of preclinical data showing accelerated tendon, ligament, and gut tissue repair — most of which sits in rodent or in-vitro studies, not in human trials.
The regulatory picture has tightened. The FDA placed BPC-157 in Category 2 on the 503A bulks list (insufficient information to evaluate), and the PCAC has heard public comment on whether it belongs there at all. Several state medical boards and the DOJ have moved against clinics and compounding pharmacies selling it for off-label injection. The MHRA has issued enforcement notices in the UK.
The clinical evidence base remains thin. Stories here cover new preclinical work, regulatory action, and any movement toward an actual registered human trial.
Investigation into the unregulated peptide market noting how easily BPC-157 can be purchased online with next-day delivery, amid celebrity endorsements from Joe Rogan and growing safety concerns.
Analyzes the announcement that ~14 of 19 peptides on FDA's Category 2 list will move back to Category 1, restoring access through licensed compounding pharmacies with a prescription.
London Standard investigation exposes consumers self-injecting BPC-157 and CJC-1295 sourced from Discord groups and online sellers, bypassing medical oversight. UK solicitors warn clinics are on 'very shaky ground.'
Updated explainer clarifying BPC-157 is not outright banned but in Category 2 requiring further investigation. Discusses potential shifts after public statements about moving peptides back to Category 1.
Physician William Meller describes treating a patient in anaphylaxis after self-injecting online peptides, and critiques RFK Jr.'s plan to move ~14 compounds off the FDA restricted list.
Investigation into men injecting BPC-157 and Thymosin Alpha-1 from unregulated internet suppliers. Doctors warn of severe allergic reactions and potential cancer risk from growth-pathway compounds.
Health Secretary Kennedy announced on Joe Rogan's podcast that the FDA will soon reclassify about 14 peptides currently restricted from compounding pharmacies, aiming to curb gray-market sourcing.
In-depth review examined 544 BPC-157 papers and found only 3 human studies and zero randomized controlled trials. Author recommends most people avoid it until stronger evidence emerges.